PHARMA NEWS, MULT...
Follow
Find
35.3K views | +103 today

5 Reasons Pharma Should Reconsider Instagram

From www.intouchsol.com

More and more, Instagram is becoming a viable social channel for pharma, if used in the right way. So here are five reasons we believe pharmas should take a new look at Instagram.

No comment yet.

Le digital : un enjeu majeur du marketing de la santé - Markentive

From www.markentive.fr

Le secteur de la santé est en plein boom digital et il est crucial pour les entreprises du domaine de sérieusement reconsidérer leur stratégie digitale
No comment yet.

What do patients want?

From worldofdtcmarketing.com

KEY TAKEAWAY: There are two things that today's patients' want in health care; empathy and to be heard.  Pharma has to find a way to take a more empathetic approach to DTC marketing if we want our ...
No comment yet.

Patient Engagement is the Blockbuster Drug of the Century

From www.forbes.com

The insight of the year goes to Leonard Kish, a health IT strategy consultant, for making that statement regarding patient engagement. The corollary to this statement is a game changer: What happens when effective patient engagement becomes the Standard of Care? Used to determine whether a doctor is liable [...]
No comment yet.

Pfizer lance la communauté My Hématologie - Buzz-esanté

From buzz-esante.fr

Le laboratoire Pfizer a lancé il y a quelques semaines, en partenariat avec la société Healthme, une communauté dédiée aux hématologues : My Hématologie.
No comment yet.

De Second Life à real life : l'immersion comme vecteur d'expérience #hcsmeufr #pactonco

From fr.slideshare.net

Présentation lors du lancement de la V2 PactOnco de Pfizer sur la réalité virtuelle, la simulation numérique à travers le concept de Metavers...
No comment yet.

L'industrie pharmaceutique traverse une période de changement #hcsmeufr

From theinnovationandstrategyblog.com

Avec le déclin lent mais effectif du modèle blockbuster dans l'industrie pharmaceutique, cette dernière peut-elle s'orienter vers le numérique pour innover ?
No comment yet.

LAB/Santé : site web dédié l'innovation par Sanofi - Buzz-esanté

From buzz-esante.fr

Le laboratoire Sanofi lance un nouveau site web dédié à l'innovation dans le domaine de la santé : le LAB/Santé.
No comment yet.

The Web Developer's SEO Cheat Sheet 3.0

From moz.com

Introducing the new and improved Web Developer's SEO Cheat Sheet. Download info on SEO best practices for online marketers and developers.
No comment yet.

Pharma And Digital Innovation: A Missed Opportunity?

From www.mediapost.com

The "Wall Street Journal" suggests that entrepreneurs and innovators are not paying enough attention to the growing and pressing needs of pharmaceutical companies in the digital health arena. But is
this really the case?
Laurent FLOURET's curator insight, May 15, 5:28 PM

"The next few years are going to be very interesting." Oh yes!!!

HEALTHCARE INNOVATION WHITE PAPER: THE BIG IDEAS SHAPING THE FUTURE OF PHARMA

From www.openhealth.co.uk

Following an inspiring meeting in June 2014 on the future of the pharma industry, David Rowley, CEO of OPEN Health has published his white paper, “Health innovation: big ideas”, a call to action to the pharma industry to innovate, adapt, flex and grow. With exciting predictions for the future of healthcare worldwide, this paper marks a sea change in the way our industry must think and act if it is to meet the fast-changing needs of patients in the real world.

No comment yet.

The State Of Digital Excellence In The Pharmaceutical Industry In 2015 Capabilities

From www.dt-associates.com

Pharmaceutical firms must adopt and consistently execute practices that lead to digital excellence and give them a competitive edge. Which of these firms are accelerating away from the rest of the marketplace? We found that only two—Merck and Bristol-Myers Squibb—are doing reasonably well and achieving excellence and maturity in their digital capability. Firms taking a disciplined approach to digital transformation achieved higher maturity in digital capability than their less-disciplined peers.
Denise Silber's curator insight, May 15, 5:23 AM

Interesting study.

Sanofi et Connecting Nurses dévoilent les résultats exclusifs de l’étude Nurses Reputation #hcsmeufr

From www.sanofi.fr

Sanofi et Connecting Nurses dévoilent les résultats exclusifs de l’étude Nurses Reputation
No comment yet.

Healthcare's omnichannel challenges | HealthWorks Collective

From healthworkscollective.com

Healthcare has a steep hill to climb in order to deliver an omnichannel patient experience.

No comment yet.

L’OMS met à jour ses listes de médicaments essentiels #hcsmeufr

From www.lequotidiendupharmacien.fr

L’Organisation mondiale de la santé (OMS) vient de publier la version 2015 de ses médicaments essentiels, y compris pédiatriques, constituée
No comment yet.

Capote Riposte : application sur la contraception d'urgence

From buzz-esante.fr

Pour sensibiliser sur la contraception d’urgence, le laboratoire HRA Pharma lance une application mobile ludique : Capote Riposte. Découverte.
No comment yet.

new report from @DeloitteUK : Connected healt How digital technology is transforming health and social care

From www2.deloitte.com

With more than 100,000 health apps, rapid growth in wearables and 70 per cent of the UK population now owning a smartphone, there is no doubt that digital technology is set to revolutionise the future of health and social care.
No comment yet.

Why Digital Health Has Not (Yet) Transformed Pharmaceutical Drug Development

From www.forbes.com

For the last several years, I’ve been arguing that digital health provides an important opportunity to improve drug development, for several reasons.

First, by providing greater insight into the patient’s actual experience of disease, these technologies can reveal important differentiating features of new therapeutics, or point out aspects of illness that new medicines ought to attack.


Second, by offering a richer readout of phenotype, digital health measurements can reveal important disease subgroups, perhaps defined by a unique underlying mechanism that can be targeted.  I’ve discussed this in detail recently, and won’t focus on this again here.

Digital health technologies can of course be helpful in a range of other ways, such as improving adherence, population analytics, clinical decision support, etc.


While some have hailed the adoption of digital health by pharma, that’s not my impression, at least on the R&D side.  In my view, it remains very much on the “innovation initiative” side of things, rather than a clear business need (like pharmacology); drug development companies may be dipping their toes in and celebrating their bravery, but at best they are interested – certainly not what I’d call “pig committed.”

No comment yet.

Patient Engagement Methods | HealthWorks Collective

From healthworkscollective.com

We are seriously considering how to incentivize patients to adhere to their care plans. This is a topic area where I have some instincts, but which of these tactics might work best?
No comment yet.

Pharma Digital Marketing Faces FDA Scrutiny on Social Media

From digitalblog.exlpharma.com

"Companies pursuing digital marketing strategies for their pharmaceutical products might want to exercise some additional caution. By now, companies are well aware that the Food and Drug Administration scrutinizes the drug claims companies make on their websites. But the regulator is also paying attention to pharma posts on social media. Recently, the FDA issued warning letters to six companies for inappropriate marketing claims they made using Facebook."

Kim Kubiak's curator insight, May 11, 10:27 AM

FDA has proposed guidelines about how pharmas can discuss products on social media. 

Comité Economique des Produits de Santé (CEPS) #leSaviezVous #hcsmeufr

From www.sante.gouv.fr

Le comité économique des produits de santé (CEPS), organisme interministériel placé sous l’autorité conjointe des ministres chargés de la santé, de la sécurité sociale et de l’économie, est principalement chargé par la loi de fixer les prix des médicaments et les tarifs des dispositifs médicaux à usage individuel pris en charge par l’assurance maladie obligatoire.
GIE_GERS's curator insight, May 10, 11:14 AM

Le comité économique des produits de santé (CEPS), organisme interministériel placé sous l’autorité conjointe des ministres chargés de la santé, de la sécurité sociale et de l’économie, est principalement chargé par la loi de fixer les prix des médicaments et les tarifs des dispositifs médicaux à usage individuel pris en charge par l’assurance maladie obligatoire.